[Calreticulin gene mutation testing in myeloproliferative neoplasms]

Calderón M, Augustovski F, Pichon-Riviere A, García Martí S, Alcaraz A, Bardach A, Ciapponi A, López A, Rey-Ares L
Record ID 32015000866
Authors' recommendations: The evidence of moderate methodological quality shows the presence of calreticulin gene mutations associated to a lower risk of thrombotic events in essential thrombocythemia and may be associated to a longer survival in primary myelofribrosis. No evidence has been found on the impact that detecting these mutations may have on the treatment approach. The presence of calreticulin gene mutations was not reported in chronic myeloid leukemia and policythemia vera; therefore, its use is not proposed. No clinical practice guidelines or health technology assessments mentioning calreticulin gene mutation testing for the management of myeloproliferative neoplasms have been found. Only one coverage policy was found and it does not recommend coverage because it is considered experimental.
Project Status: Completed
Year Published: 2015
URL for published report: www.iecs.org.ar/home-ets/
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Argentina
MeSH Terms
  • Mutation
  • Myeloproliferative Disorders
  • Primary Myelofibrosis
  • Thrombocythemia, Essential
Organisation Name: Institute for Clinical Effectiveness and Health Policy
Contact Address: Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name: info@iecs.org.ar
Contact Email: info@iecs.org.ar
Copyright: Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.